Neurology · Atlanta area, GA
Neurology studies in Atlanta area, GA
71 recruiting studies have a site in the Atlanta area. This page includes nearby cities such as Decatur, Marietta, Sandy Springs, Alpharetta.
71 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
1 study with pay posted
Exact amounts posted by the research company for each study. The button opens that study’s own page.
Pays up to
$8,150
Parkinson’s Disease Study
CenExel · Decatur, GA
Ages 45–80 · Male/Female
View study & apply (opens in a new tab)Opens CenExel’s page for this exact study
More recruiting studies (pay not posted)
- RecruitingHealthy volunteersPhase 1/Phase 2
Digital STEADI Efficacy
Friendi.fi Corporation
- Location
- Atlanta, GA
- Eligibility basics
- Ages 50+
- RecruitingHealthy volunteersPhase 1
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Eli Lilly and Company
- Location
- Atlanta, GA + 5 other US sites
- Eligibility basics
- Ages 45–85
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Atlanta, GA + 35 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
RapidPulse, Inc
- Location
- Atlanta, GA + 12 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Regeneron Pharmaceuticals
- Location
- Atlanta, GA + 41 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Rapport Therapeutics Inc.
- Location
- Atlanta, GA + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Merck Sharp & Dohme LLC
- Location
- Decatur, GA + 34 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Atlanta, GA + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Atlanta, GA + 34 other US sites
- Eligibility basics
- Ages 55–95
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Atlanta, GA + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 4
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Alpha Cognition, Inc
- Location
- Decatur, GA + 21 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Atlanta, GA + 56 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Atlanta, GA + 111 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Decatur, GA + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Regeneron Pharmaceuticals
- Location
- Atlanta, GA + 42 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Atlanta, GA + 35 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Atlanta, GA + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Smyrna, GA + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Atlanta, GA + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Aspeya, Inc.
- Location
- Atlanta, GA + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Atlanta, GA + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Atlanta, GA + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Regeneron Pharmaceuticals
- Location
- Atlanta, GA + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Decatur, GA + 31 other US sites
- Eligibility basics
- Ages 55–90
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.